$Ginkgo Bioworks (DNA.US)$ This plan is all in @0 .3931, but...
$Ginkgo Bioworks(DNA.US$ This plan is all in @0 .3931, but looking at the chip distribution and turnover rate on the market these days, it is estimated that the passive ETF holdings reduction caused by being transferred out of the Russell 3000 should be about the same, and the empty side's holdings are also gradually decreasing, and it shouldn't be too far from the bottom. Meanwhile, today's Quadruple Witching Hour, once the institutional end-of-season position adjustment day has passed, the trend may calm down and enter a consolidation period. Ready to go!
Never think about it; you must buy the long-term ones you like at the lowest point. Decisively increase your positions during the day.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
小蛙_Slash : Why are you still buying him
北美深蓝 OP 小蛙_Slash :
In the long run, I am optimistic about the company's industry sector and the company's position in the industry.
As a platform-based enterprise, the company's data ownership in the industry is at the leading level. From a certain perspective, the scale of data is one of the key factors in determining a company's growth potential. In addition, the company has further strengthened its strength and development potential through mergers and acquisitions of promising companies, such as Zymergen, which was previously acquired. The development of an enterprise is inseparable from an excellent management team, including management and decision makers, including many of the company's co-founders, and is also the core competitiveness of the company's future development...
Similar to Nvidia and AMD, which were at a low point many years ago, although the two are not entirely comparable, it also shows that the company's industry circuit is critical. I am optimistic about companies that not only have high-quality tracks, but also have huge data scales and can fully tap the potential of data. I think$Ginkgo Bioworks (DNA.US)$ It's one of them.
北美深蓝 OP : Of course, what I'm talking about here is not just a single shareholding full position$Ginkgo Bioworks (DNA.US)$ Instead, it's all in with usable/adjustable liquidity, and I'm still in heavy positions$NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) (NAMSW.US)$ , before the merger commenced~![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
QianmengYu : The main business of this company does not have any commercial products until now, and now it relies on PhDs to do professional services. The company was acquired to acquire a product line. Either the main leaders are mentally ill and treat shareholders' money as grants and never deliver, or the platform is fatally flawed. When the stock price falls, it is impossible to make money; this kind of company is going bankrupt and liquidated. Once they have commercialized it, it is only reasonable to follow up at a premium. I had one before that was dragged to death